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Objective: Myocardial injury after ischemia and reperfusion may be medi-
ated, in part, by oxygen-derived free radicals. In this study the protective
effects of extracellular superoxide dismutase overexpression were directly
assessed in the hearts of transgenic mice, after ischemia and reperfusion
injury, using an isolated work-performing murine heart preparation and
computerized analysis of functional data. Methods: A blinded study was
performed to compare cardiac function in the hearts of both transgenic
mice with a 3.5-fold overexpression of myocardial extracellular superoxide
dismutase (n 5 6, 22 to 26 gm) and littermate controls (n 5 8, 22 to 26 gm).
Preload-dependent cardiac output, contractility, heart rate, stroke work,
and stroke volume were evaluated in the two groups before and after a
6-minute period of normothermic ischemia. Results: No differences were
found between extracellular superoxide dismutase hearts and control
hearts in any parameter of myocardial function before ischemia. After
ischemia, decreases in cardiac output occurred in both groups; however,
this decrease was larger in control mice compared with extracellular
superoxide dismutase mice. A higher percentage of recovery was also
observed in the contractility, heart rate, stroke work, and stroke volume of
extracellular superoxide dismutase hearts compared with control hearts.
Conclusion: After global normothermic ischemia and subsequent reperfu-
sion, decreases in cardiac function occurred in both extracellular superox-
ide dismutase and control mice; however, a higher percentage of recovery
was observed in the extracellular superoxide dismutase overexpressed
hearts. These data suggest that extracellular superoxide dismutase trans-
gene overexpression significantly improves preservation of myocardial
function after ischemia and reperfusion injury. (J Thorac Cardiovasc Surg
1998;115:450-9)
Myocardial injury after ischemia and reperfusionmay be mediated by oxygen-derived free radi-
cals and is supported by the observation that signif-
icant quantities of these radicals are generated
during postischemic reperfusion. Such species in-
clude the superoxide anion, hydrogen peroxide, the
hydroxyl radical, and the peroxynitrite anion. These
radicals damage normal tissue through the peroxi-
dation of lipids and oxidation of sulfhydryl groups,
which eventually leads to deficiencies in cell mem-
brane permeability and enzyme function.1
Several nonenzymatic and enzymatic defense
mechanisms occur naturally in aerobic organisms to
potentially protect against oxidant-mediated injury.
Nonenzymatic antioxidant substances include vita-
min E, vitamin C, vitamin B, and b-carotene.2
Enzymatic antioxidants include catalase and gluta-
thione, which both detoxify hydrogen peroxide
through separate biochemical pathways. Superoxide
dismutase (SOD) represents a third enzymatic anti-
oxidant that has been shown to catalyze the dismu-
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tation of the superoxide anion to hydrogen peroxide
and molecular oxygen.3
Controversy remains, however, as to the extent
that antioxidants protect the heart after ischemia
and reperfusion injury. Recent developments in
transgenic technology represent a unique strategy
for elucidating any role individual antioxidants may
play in preserving myocardial function in this set-
ting. This study was therefore designed to directly
assess the myocardial protective effects of extracel-
lular superoxide dismutase (EC-SOD) overexpres-
sion in the hearts of transgenic mice after ischemia
and reperfusion injury, using an isolated work-
performing murine heart preparation4 and comput-
erized analysis of functional data.
Materials and methods
Study design, experimental groups, and generation of
transgenic mice. In a blinded study, six transgenic mice
with myocardial overexpression of the human EC-SOD (2
to 4 months, 22 to 26 gm) were evaluated and compared
with eight littermate control mice (CTL, 2 to 4 months, 22
to 26 gm) in terms of preischemic and postischemic
cardiac function.
The transgenic mice used in this investigation had
previously been created by Oury and associates5 by use of
an expression vector comprised of the human b-actin
promoter coupled to a full-length cDNA encoding for the
human EC-SOD. This linearized transgene construct was
microinjected into the pronuclei of fertilized single-cell
mouse embryos, which were then reimplanted into the
oviduct of an adult female mouse. Offspring were
screened for the presence of the transgene by Southern
blot and/or polymerase chain reaction analysis of tail
DNA. A founder mouse was bred with B6C3 (F1) mice.
Myocardial expression of human EC-SOD messenger
RNA in the transgenic mice used in this report was
confirmed using a well-established technique of reverse
transcriptase polymerase chain reaction.6 Cytochrome c
reduction inhibition7 was used to measure myocardial
EC-SOD activity in both transgenic and nontransgenic
hearts.5
Isolated work-performing murine heart apparatus.
The isolated work-performing (Langendorff) murine
heart preparation (Fig. 1) used for acquisition of func-
tional data in this study is previously well described.4 An
in-line ultrasonic 2N flow probe (Transonic System, Inc.,
Ithaca, N.Y.) was connected to the aortic root cannula to
measure aortic flow. Aortic and left atrial pressures were
measured with in-line 5F micromanometers (Millar In-
struments, Inc., Houston, Tex.). Transition from retro-
Fig. 1. The isolated work-performing murine heart preparation. The key features of this system include
jacketed water baths, reservoirs, and water lines to minimize heat loss; an in-line ultrasonic flow probe to
measure cardiac output; aortic and left atrial (LA) micromanometers; and a computerized data acquisition
and analysis system.
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grade perfusion (through the aortic cannula) to antegrade
perfusion (through the left atrial cannula) or vice versa
was easily done in the same heart by clamping off one
system while the other was being used. The isolated heart
was immersed in a jacketed, 38° C water bath filled with
Krebs-Henseleit solution (composed of 118 mmol/L NaCl,
4.7 mmol/L KCl, 7 mmol/L MgSO4, 1.2 mmol/L KH2PO4,
7 mmol/L NaHCO3, 11.1 mmol/L glucose, 3 mmol/L
CaCl2, and 0.5 mmol/L NaEDTA). Krebs-Henseleit solu-
tion was also circulated in the apparatus and maintained
at an average temperature between 38.0° C and 38.5° C
using an in-line water pump and heating coils. Blind-
tipped catheters were used to oxygenate the buffering
solutions in the reservoirs with 95% oxygen and 5%
carbon dioxide. Blood gases of the buffered solutions were
checked periodically throughout the experiments to en-
sure physiologic levels of pH, oxygen, carbon dioxide, and
electrolytes (Gem-Stat Mallinckrodt Sensor Systems, Ann
Arbor, Mich.).
Anesthesia and operation. The anesthetic regimen and
operative procedure have been previously well described.4
A clam-shell incision was made to expose the mediasti-
num and pleural cavities, and the thymus was bluntly
dissected off the pericardium. The pericardium was
opened, and the heart was cold arrested with 4° C Krebs-
Henseleit solution and excised from the chest. The aortic
root was then cannulated with a 2 mm 20-gauge angio-
catheter at the level of the innominate artery.
Experimental protocol. Retrograde perfusion was im-
mediately begun with warm Krebs-Henseleit solution and
maintained at a pressure of 60 mm Hg to ensure adequate
coronary artery perfusion. After 5 minutes of retrograde
perfusion, to allow for temperature equilibration, the left
atrium was cannulated in a posterior fashion, and the
heart was subsequently perfused in an antegrade (or
work-performing) manner against an afterload of 55 mm
Hg.4, 8
A preload-dependent work-performing experiment was
performed in both EC-SOD and CTL hearts according to
the following protocol. Preload was gradually increased by
raising the height of the antegrade perfusate reservoir,
with respect to the left atrium, in 5 mm Hg pressure
increments from 5 to 25 mm Hg. At each preload level,
left atrial pressure, aortic pressure, and aortic flow data
were collected over several cardiac cycles by computer
acquisition. After data collection at 25 mm Hg, the left
atrial pressure was slowly lowered to approximately 10 to
12 mm Hg. Antegrade perfusion was continued for an
additional 5 minutes to allow the hearts to recover from
any temporary dysfunction that may have potentially been
caused by the extreme loading conditions at 20 to 25 mm
Hg.
All hearts were then subjected to 6 minutes of normo-
thermic (38° C) ischemia, which was achieved by clamping
the aortic and left atrial lines. Immediately after ischemia,
the hearts were perfused in a retrograde manner for 10
minutes, which was subsequently followed by antegrade
perfusion for another 10 minutes at a preload of 10 mm
Hg. The preload-dependent work-performing experiment
was again performed to obtain postischemic left atrial
pressure, aortic pressure, and aortic flow.
Data acquisition and analysis. All functional and he-
modynamic data were digitized on-line at 500 Hz and
filtered by a 50 Hz low-pass filter, collected, and stored on
a microprocessor (PDP 11/23, Digital Equipment Corp.,
Maynard, Mass.). Raw data were analyzed on a VAX
station 3100 computer (Digital Corp, Hitachi, Japan) with
software developed in our laboratory, which is previously
well described.4 Measured on-line parameters included
aortic pressure, cardiac output (left ventricular output
minus coronary flow), left atrial pressure, and heart rate.
Other parameters used to assess preischemic and post-
ischemic myocardial performance were derived from
these measured values and included the first derivative of
pressure with respect to time (dP/dt), stroke volume, and
stroke work.
In both CTL and EC-SOD hearts, the average values
for each parameter of myocardial performance were
calculated from the individual values at preload levels of
5, 10, 15, 20, and 25 mm Hg. The percent recovery of each
parameter after normothermic ischemia was calculated by
dividing the average postischemic value of a specific
parameter by its preischemic value.
Myocardial water content. To calculate myocardial wa-
ter content, every heart was weighed after collection of
postischemic preload-dependent functional data, placed
in a 120° C oven, and dried for 24 hours. The dry weight
of each heart was then obtained. Myocardial water con-
tent was calculated from the following equation:
Myocardial water content 5
~Wet weight – Dry weight!
Wet weight
3 100%
Experimental approval and animal rights. The exper-
imental setup and procedures conformed to the guidelines
established by the American Physiological Society and the
National Institutes of Health (“Guide for the Care and
Use of Laboratory Animals,” National Institutes of
Health Publication No. 86-23, revised 1985). The experi-
ments were approved by the Duke University Institutional
Animal Care and Use Committee (DUIACUC Assigned
Registry A485-95-7).
Statistical analysis. Statistical analysis was performed
using commercially available software (SigmaStat Version
2.0, Jandel Scientific Software, San Rafael, Calif.). To test
for a trend in the various indices of myocardial perfor-
mance over the entire range of increasing preloads, both
before and after normothermic ischemia, a linear multi-
variate analysis of repetitive measurements was used.
Bonferroni’s method was used to compensate for the
increased risk of a type I error with multiple comparisons.
Because this analysis does not indicate which periods
differ, follow-up comparison between functional parame-
ters at individual preload levels was performed with
paired Student’s t tests. Paired Student’s t tests were also
used to compare the average preischemic data with the
average postischemic data within each group. Unpaired
Student’s t tests were used to compare all data between
the EC-SOD and CTL groups. The results are expressed
as mean 6 standard error of the mean. A difference was
considered statistically significant at p , 0.05.
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Results
Reverse-transcriptase polymerase chain reaction
demonstrated that myocardial expression of human
SOD messenger RNA was present in the transgenic
mice and absent in the control mice (Fig. 2). EC-
SOD activity was previously found to be 3.5-fold
higher in transgenic hearts compared with control
hearts.5 Gross examination of both groups revealed
no obvious differences in phenotype, breeding, or
life span between EC-SOD and CTL mice.
After hypothermic arrest and excision, an average
time of 2 6 0.5 minutes was required to cannulate
the aorta and connect the heart to the Langendorff
apparatus. Mechanical activity resumed almost im-
mediately on initiation of retrograde perfusion with
warm Krebs-Henseleit solution. No external pacing
was required throughout the experiments.
Myocardial function before and after normother-
mic ischemia. Before ischemia, increases in cardiac
output were observed in association with increases
in preload levels for both CTL and EC-SOD mice
(Fig. 3). No significant differences were found in the
preischemic cardiac outputs of normal and trans-
genic hearts, which ranged from approximately 3.3
and 6.0 ml/min. After normothermic ischemia, sig-
nificant decreases in cardiac output were observed
in both groups; however, this decrease was signifi-
cantly greater in the CTL group compared with the
EC-SOD group (Fig. 3). As a result, the postisch-
emic cardiac output of EC-SOD hearts was signifi-
cantly greater compared with CTL hearts at pre-
loads of 5, 10, 15, and 25 mm Hg. Before ischemia,
the average cardiac outputs were not significantly
different between CTL (5.40 6 0.56 ml/min) and
EC-SOD mice (5.11 6 0.23 ml/min). After ischemia,
significant decreases in the average cardiac output
were observed in both CTL and EC-SOD hearts;
however, the average postischemic cardiac output of
EC-SOD hearts (3.78 6 0.28 ml/min) was signifi-
cantly higher when compared with the average
postischemic cardiac output of CTL hearts (2.73 6
0.26 ml/min, p 5 0.02).
The average contractility was not significantly
different between the two experimental groups be-
fore ischemia (Fig. 4). Significant decreases oc-
curred in the average contractility of both CTL and
EC-SOD hearts after normothermic ischemia. In
addition, the postischemic contractility of EC-SOD
mice was higher in comparison with CTL mice;
however, this difference was not statistically signifi-
cant.
The average stroke work values did not differ
significantly between CTL hearts and EC-SOD
hearts before normothermic ischemia. After isch-
emia, significant decreases were observed in both
Fig. 2. Reverse-transcriptase polymerase chain reaction
analysis. Using this technique, myocardial expression of
the 174 base pair (bp) human extracellular superoxide
dismutase messenger RNA was found to be present in
transgenic mice (E) and absent in control (C) mice.
Fig. 3. The preischemic and postischemic cardiac outputs
(CO) of both experimental groups are plotted against
gradually increasing preload levels at a constant afterload
of 55 mm Hg. Before ischemia, no significant differences
were observed in the CO of CTL mice compared with
EC-SOD mice. Significant decreases in CO were observed
for both groups after normothermic ischemia; however,
this decrease was significantly larger in CTL hearts com-
pared with EC-SOD hearts. *Denotes p , 0.05 versus
EC-SOD-Pre. †Denotes p , 0.05 versus CTL-Post. ‡De-
notes p , 0.01 versus CTL-Pre.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 2
Chen et al. 4 5 3
CTL and EC-SOD mice; however, the average
postischemic stroke work of EC-SOD hearts was
significantly higher compared with CTL hearts. The
differences in the average stroke work between the
two experimental groups, before and after ischemia,
are displayed in Fig. 5.
On average, the heart rates ranged from 430 to
490 beats/min in both experimental groups. No
significant differences were found in the average
heart rates between CTL and EC-SOD hearts be-
fore ischemia (Fig. 6). Significant decreases were
observed in the heart rates of both CTL and EC-
SOD mice after normothermic ischemia. Although
the postischemic heart rates of EC-SOD hearts were
increased compared with CTL hearts, these differ-
ences were not statistically significant.
Before ischemia, no significant differences in the
average stroke volume were observed between CTL
mice and EC-SOD mice. After ischemia, a signifi-
cant decrease in the stroke volume for both CTL
and EC-SOD hearts was observed. The postisch-
emic stroke volume of EC-SOD mice, however, was
significantly greater compared with the postischemic
stroke volume of CTL mice (Fig. 7).
Myocardial water content and percent recovery of
postischemic myocardial function. No significant
differences were observed in the myocardial water
content between CTL (80.37% 6 0.36%) and EC-
SOD hearts (81.22% 6 0.65%). The percent recov-
ery of each individual parameter of myocardial
performance after normothermic ischemia was sig-
nificantly larger in the EC-SOD hearts compared
with the CTL hearts. These differences in postisch-
emic functional recovery between the two experi-
mental groups are summarized in Table I.
Discussion
EC-SOD represents one of three distinct types of
SOD isoenzymes known to exist in mammalian
species. First identified in plasma9, 10 and later
found to exist primarily in the extracellular matrix of
tissues,11 EC-SOD has a relatively low distribution
in solid organs compared with the other two SOD
isoenzymes, copper-zinc SOD and manganese SOD.
It does, however, constitute the predominant form
of SOD in vascular tissue, accounting for up to 70%
of total SOD activity, not only in the systemic and
pulmonary arteries but also in the coronary circula-
tion.12 EC-SOD becomes evenly distributed within
the vascular walls after secretion from smooth mus-
cle cells, which make up the principal source of this
enzyme.12 Although the regulation and importance
of both copper-zinc SOD and manganese SOD as
antioxidants has been extensively studied and clearly
established, the physiologic significance of EC-SOD
is, at present, not completely understood.5
Numerous investigations have attempted to de-
fine the protective role of EC-SOD, particularly
with respect to preserving myocardial function in the
setting of ischemia and reperfusion injury.13-17 Myo-
cardial preservation by EC-SOD after ischemia and
Fig. 4. The differences in the average contractility (dP/dt)
between the two experimental groups before and after
normothermic ischemia. The average dP/dt decreased
significantly in both EC-SOD and CTL hearts after nor-
mothermic ischemia. *Denotes p , 0.001 versus CTL,
Pre-ischemia. †Denotes p 5 0.04 versus EC-SOD, Pre-
ischemia.
Fig. 5. The differences in the average stroke work (SW)
between the two experimental groups before and after
normothermic ischemia. The decrease in the average SW
of CTL hearts after ischemia was significantly greater
compared with the decrease in the average SW of EC-
SOD hearts. *Denotes p 5 0.003 versus CTL, Pre-isch-
emia. †Denotes p 5 0.005 versus EC-SOD, Pre-ischemia.
‡Denotes p 5 0.02 versus CTL, Post-ischemia.
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reperfusion injury, however, has been disputed. Al-
though some investigators have reported a benefi-
cial effect,14, 17 others have failed to document any
protection.15, 18 This controversy may be related to
the method in which the enzyme was administered.
In those previous studies, EC-SOD, as well as other
antioxidants, was given exogenously at various time
intervals around the period of ischemia and reper-
fusion. These inconsistent approaches among the
various investigators would not allow one to draw
any firm overall conclusions regarding EC-SOD’s
protective effect.
Recent advances in molecular biology and in vivo
genetic transfer techniques have led to the develop-
ment of several transgenic animal models with ei-
ther overexpression or underexpression of very spe-
cific genes in the mammalian genome. With respect
to myocardial performance, such models have be-
come powerful tools for investigating both normal
and altered cardiac physiology and have already led
to the greater understanding of adrenergic receptor
signaling pathways,19 the effects of a-skeletal actin
overexpression on myocardial contractile function,20
and the biochemical triggers responsible for induc-
ing ventricular hypertrophy.21 The knowledge
gained from such studies has led others to apply this
technology further toward developing efficient gene
transfer techniques as potentially promising new
therapies in the treatment of a number of acquired
cardiovascular disorders.22, 23 Thus overexpression
of the EC-SOD in myocardial tissue using a trans-
genic model appears to offer a unique strategy for
first investigating the myocardial protective effects
of EC-SOD after ischemia and reperfusion injury.
The isolated work-performing heart (Langen-
dorff) preparation represents a highly sensitive and
previously validated model of evaluating both pre-
ischemic and postischemic cardiac function in iso-
lated murine hearts.4 In contrast to other Langen-
dorff systems, the present apparatus uses both
micromanometers and an ultrasonic flow probe in
combination with computerized data acquisition.
Such high-fidelity instruments allow for the record-
ing of heart rates of up to 1500 to 1800 beats/min
and for analysis of very sensitive parameters of
myocardial performance such as stroke work.4 In
the only other well-described isolated work-per-
forming heart preparation used for evaluating myo-
cardial performance in murine hearts, fluid-filled
pressure catheters were used to obtain intracavitary
pressures, contractility, and heart rates.8 Because
the physiologic heart rates observed in this study
ranged from 400 beats/min to more than 500 beats/
min, application of such catheters in this setting
might lead to dampening and distortion of the
pressure waveforms, as well as a decreased fre-
quency response at the time of data acquisition.
A potential criticism of this model is that Krebs-
Henseleit solution, instead of blood, was used for
both retrograde and antegrade myocardial perfu-
sion. A blood-perfused, isolated work-performing
Fig. 6. The differences in the average heart rates (HR)
between the two experimental groups before and after
normothermic ischemia. The average HR decreased sig-
nificantly in both EC-SOD and CTL hearts after normo-
thermic ischemia. *Denotes p 5 0.03 versus CTL, Pre-
ischemia. †Denotes p 5 0.03 versus EC-SOD,
Pre-ischemia.
Fig. 7. The differences in the average stroke volume (SV)
between the two experimental groups before and after
normothermic ischemia. The decrease in the average SV
of CTL hearts after ischemia was significantly greater
compared with the decrease in the average SV of EC-
SOD hearts. *Denotes p 5 0.002 versus CTL, Pre-isch-
emia. †Denotes p 5 0.006 versus EC-SOD, Pre-ischemia.
‡Denotes p 5 0.03 versus CTL, Post-ischemia.
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murine heart preparation would certainly be more
physiologic than use of any crystalloid solution. The
glutathione in red blood cells might also substan-
tially limit the ischemia and reperfusion-induced
burst of oxygen-derived free radicals and subse-
quent cardiac injury. Although the present design
can potentially exaggerate myocardial damage after
ischemia and subsequent reperfusion, such condi-
tions were identical for both experimental groups. In
addition, it must be pointed out that set up of the
Langendorff system in this report before actual
experimentation requires at least 1500 to 1800 ml of
priming solution. Thus an inordinate number of
mice, given the small body size and plasma volume,
would be needed to obtain enough blood for one set
of experiments. Even if dilute blood were used as
the perfusate, such requirements seem somewhat
impractical.
Before ischemia, no significant differences were
observed in any parameter of cardiac function be-
tween the two experimental groups. Significant de-
creases in myocardial performance were observed in
both transgenic and nontransgenic hearts after
global normothermic ischemia; however, these de-
creases were significantly greater in the nontrans-
genic hearts compared with the transgenic hearts.
As a result, the postischemic recovery of each
measured parameter of cardiac function was signif-
icant greater in mice with myocardial overexpres-
sion of EC-SOD compared with littermate CTL
mice.
Thus transgenic overexpression of EC-SOD in
isolated murine hearts does not appear to affect
baseline myocardial performance compared with
normal hearts. The significantly higher percent re-
covery of postischemic function, observed in hearts
overexpressing EC-SOD, suggests that this specific
antioxidant may have an important role in preserv-
ing myocardial function after ischemia and reperfu-
sion injury. Additional insight could be gained if
myocardial recovery were also assessed in mice with
greater than 3.5-fold overexpression of EC-SOD;
however, creation of such an animal has not been
previously described.
The decision to use a 6-minute period of global
normothermic ischemia was made after a series of
preliminary studies in which the ischemic interval
was varied from 4 to 7 minutes in normal murine
hearts. A dose-response curve was subsequently
generated, demonstrating that 4 to 5 minutes of
ischemia resulted in a 25% to 30% decrease in
cardiac output, whereas 6 minutes led to a reduction
in cardiac output of 45% to 50%. In addition, no
appreciable functional recovery was observed in
control hearts after 7 minutes of global ischemia.
Because it was initially unclear as to what effect
myocardial EC-SOD overexpression would have on
postischemic recovery of cardiac performance, 6
minutes was believed to be the most appropriate
period of normothermic ischemia for this study. One
can argue that such a brief period of ischemia has
little clinical relevance to the clinical setting. It
should be pointed out, though, that the purpose of
these preliminary studies was only to determine a
period of ischemia that would lead to a significant
reduction of cardiac performance in murine hearts
to adequately assess the myocardial protective ef-
fects of EC-SOD.
Nonetheless, it was somewhat surprising that the
control hearts in this study were so sensitive to
ischemia, requiring only 6 minutes to effect a 50%
reduction in preload-dependent myocardial perfor-
mance. This finding, however, is consistent with
another investigation involving normal wild-type
murine hearts, in which a 40% recovery of devel-
oped pressure was observed after 6 minutes of
global ischemia.24 On the other hand, previous
studies using rat hearts have shown that at least 15
Table I. Percent recovery (% Rec) of preload-dependent myocardial function after normothermic ischemia
CO (% Rec) SW (% Rec)
dP/dt
(% Rec) HR (% Rec) SV (% Rec)
CTL 49.66 (2.40) 54.78 (2.95) 78.15 (1.86) 87.04 (1.97) 54.15 (2.80)
EC-SOD 73.25* (3.27) 77.41* (3.96) 90.15† (3.61) 94.33‡ (2.03) 77.90* (3.90)
CO, Cardiac output; SW, stroke work; dP/dt, average contractility; HR, heart rate; SV, stroke volume; CTL, control hearts; EC-SOD, extracellular superoxide
dismutase overexpressed hearts.
*p , 0.001 versus CTL.
†p 5 0.01 versus CTL.
‡p 5 0.03 versus CTL.
SEM in parentheses.
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to 30 minutes of normothermic ischemia is required
to impair myocardial function by 50%.17, 22, 25, 26 A
potential explanation for this apparent discrepancy
may lie in the differences in baseline heart rates
between these two species.
In an earlier investigation comparing adenosine
triphosphate (ATP) depletion and mitochondrial
functional loss during ischemia between slow (dog)
and fast (rat) heart-rate hearts, Rouslin and associ-
ates27, 28 demonstrated that slow heart-rate hearts
use a more diverse set of mechanisms for conserving
ATP during ischemia than fast heart-rate hearts,
which includes a mitochondrial F1-ATPase inhibitor
protein. Fast heart-rate hearts generally rely on a
single mechanism for maintaining high-energy phos-
phate during ischemia, namely, anaerobic glycoly-
sis.27 These differences suggest that the greater
diversity of mechanisms for conserving ATP used by
slow heart-rate hearts may be a more effective
strategy for maintaining cellular ATP stores and
thereby preserving cellular function during isch-
emia.27
Admittedly, mice, along with rats, are fast heart-
rate animals.28 Nevertheless, a marked difference
exists in the heart rates between these two species.
Previous studies demonstrate that baseline rat heart
rates range from approximately 230 to 270 beats/
min,17 which are much slower than the murine heart
rates of 430 to 490 beats/min observed in this report.
Thus the observed sensitivity of murine hearts to
brief periods of ischemia compared with rat hearts
could be due to a much faster depletion of high-
energy phosphates resulting from higher metabolic
demand. Quantitation of myocardial ATP levels in
murine hearts during progressively longer periods of
ischemia from 4 to 7 minutes may provide a bio-
chemical explanation for the rapid decline in func-
tion, but these comparisons require further investi-
gation.
The present findings might initially appear to
contradict those in the original description of the
isolated work-performing murine heart preparation,
in which a 7-minute period of ischemia in normal
murine hearts resulted in a 22% to 24% reduction in
cardiac output and stroke work and no significant
changes in either the heart rates or stroke volumes.4
It is important to keep in mind, however, that all
hearts in this report were subjected to periods of
ischemia that occurred under normothermic condi-
tions at 38° C. In the previous study, hearts were
exposed to warm, and slightly hypothermic, temper-
atures of 32° C during the 7-minute ischemic inter-
val. Thus the degree of injury was not precisely
identical for the two studies, and any differences in
the recovery of postischemic myocardial perfor-
mance would certainly be expected.
It would be interesting to determine whether
periods of hypothermic ischemia would have effects
on EC-SOD overexpressed hearts similar to normo-
thermic ischemia because this scenario is quite
analogous to the clinical setting in which cardiople-
gia is often used to induce a period of hypothermic
arrest at the time of cardiac surgery. Unfortunately,
one cannot predict, from the data presented,
whether these transgenic mice would respond to
hypothermia in a comparable manner to the way
they recovered from normothermic ischemia. Any
conclusions regarding such a response necessitate
additional investigation.
The significant protective effect of EC-SOD ob-
served at the physiologic level in this report warrants
further investigation into the potential biochemical
mechanisms behind such protection. A compelling
mechanistic thread could be constructed if signifi-
cantly lower levels of oxygen-derived free radicals
and decreased oxidant-mediated injury (through
lipid peroxidation and sulfhydryl group oxidation)
were documented in hearts of transgenic mice after
ischemia and reperfusion injury. Such mechanisms,
however, were not the subject of these experiments;
the goal of this report was to first establish a
physiologic protective effect. It would be prudent to
next proceed into examining the molecular mecha-
nisms behind EC-SOD’s myocardial protective ef-
fects. Although purely speculative, this information
could eventually be applied clinically for administer-
ing EC-SOD, through the use of gene transfer
techniques, as a novel therapy in treating myocardial
ischemia and reperfusion injury.
In summary, transgenic overexpression of human
EC-SOD in isolated murine hearts does not appear
to affect baseline myocardial performance com-
pared with normal hearts. After global normother-
mic ischemia and subsequent reperfusion, signifi-
cant decreases in cardiac function were observed in
both transgenic and nontransgenic hearts. A signif-
icantly higher percentage of functional recovery,
however, was observed in EC-SOD overexpressed
hearts. The experimental model should now be
applied in assessing potential biochemical mecha-
nisms, occurring by way of the antioxidant pathways
of EC-SOD, which may play an important role in the
preservation of myocardial function after ischemia
and reperfusion injury.
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Discussion
Dr. Pedro J. del Nido (Boston, Mass.). First of all, I
congratulate you for using a model that more directly
addresses the question of the role of SOD in ischemia-
reperfusion, and I would encourage the use of this kind of
model. The problem, however, is that compensatory
mechanisms always occur in these transgenic animals.
My first question relates to the fact that it is known that
these animals live longer and, therefore, age more slowly.
You have weight-matched animals. Are they age-matched
as well? In other words, are you comparing younger
animals to older animals simply because you use weight as
your control?
And the second question is, what about other antioxi-
dant enzymes? If you up-regulated SOD, do you also have
up-regulation of catalase or glutathione peroxidase, which
is what one would expect in this model?
Dr. Chen. Thank you, Dr. del Nido. We certainly agree
with you that transgenic overexpression represents a
very unique and direct model as well. Several of the
other reports that have been published regarding the
potential protective effects of EC-SOD have involved
exogenous administration around the ischemic period.
We believe the different methods used by different
investigators would not allow for any firm overall
conclusions.
These mice were actually age-matched. And by gross
examination, no difference was observed in the phenotype
or life span between EC-SOD and CTL mice.
As far as other compensatory mechanisms, that is
certainly something we had considered as well.
Regarding the other two types of SOD isoenzymes,
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copper-zinc SOD and manganese SOD, no difference in
expression was observed between the transgenic and
nontransgenic mice. We had planned to assess catalase
and glutathione activity between the two groups; however,
that has not been done at this time.
Dr. John E. Mayer, Jr. (Boston, Mass.). What if you
turn the experiment around the other way, have you made
knockout mice for this enzyme?
Dr. Chen. That was a very good point that we recog-
nized as well along with our collaborators. Those mice
have been created; however, they have not been studied
on this apparatus.
Dr. Yoshifumi Naka (New York, N.Y.). Have you looked
at the biochemical parameters that could suggest reduc-
tion of superoxide amount?
Dr. Chen. We have not. In this study these hearts were
weighed and then oven-dried to obtain dry weights. We
then calculated myocardial water content, which was not
significantly different between the two groups. We had
planned another set of experiments in which we would
subject additional hearts to these same experimental
conditions and assess biochemical levels of oxidant-free
radicals and SOD activity.
Dr. Naka. Have you tried similar experiments using the
transgenic mice with EC-SOD–like protein that is en-
coded similar to EC-SOD but different from EC-SOD?
That is why this protein has the same molecular weight
and a similar one-dimension configuration but no or little
affinity to SOD. My point is that you demonstrated
starting and end points of the black box, superoxide
dismutation by EC-SOD, by showing improved physio-
logic parameters, but you have shown no direct evidence
of this phenomenon. A theoretical concern is that over-
expressed and increase protein may cause improved func-
tion.
Dr. Chen. We have not examined other types of trans-
genic mice with proteins or enzymes that are similar in
structure to EC-SOD but do not contain the activity.
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